Arrowhead Pharmaceuticals(ARWR)

PASADENA, CAPharmaceutical1 H-1B visas (FY2023)

Focus: Arrowhead Pharmaceuticals is a public biotech company headquartered in Pasadena, CA, specializing in RNAi therapeutics for gene therapy and neurology indications. The company is generating ~$240M in annual revenue with a diversified pipeline of 23 programs across rare and chronic disease areas.

Gene Therapy Neurology

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

Should You Work at Arrowhead Pharmaceuticals?

AI assessment

Strong scientific opportunity for RNA therapeutics specialists willing to accept financial risk; best suited for early-career researchers or mission-driven scientists rather than those prioritizing salary growth or tenure security.

Why Work Here

Leading RNAi platform with proven commercial traction: REDEMPLO (plozasiran) launched in 2025 for severe hypertriglyceridemia with 15-year exclusivity runway (LOE 2038)

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Late-stage

5 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

4 open

Revenue

$241M

Key Products

REDEMPLO

Severe Hypertriglyceridemia; Familial Chylomicronemia Syndrome

Growth

Help build intelligence for Arrowhead Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

No Intervention

COVID-19

N/A

Clinical Trials (1)

NCT05859958ABO Blood Group Type Association With COVID-19 Severity

N/A

Boceprevir

Hepatitis C Infection

N/A

Clinical Trials (1)

NCT01465516Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir

N/A

Sofosbuvir and simeprevir

Hepatitis C

N/A

Clinical Trials (1)

NCT02485262Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience

N/A

Difference in development of Acute Lung Injury in Amphetamine positive and negative patients

Burns

N/A

Clinical Trials (1)

NCT05611385Amphetamine Induced Adult Respiratory Distress Syndrome

N/A

Mortality and Morbidity Associated With New Onset Acute Kidney Injury in Critically Ill COVID-19 Inf

Acute Kidney Injury

N/A

Clinical Trials (1)

NCT05964088Mortality and Morbidity Associated With New Onset Acute Kidney Injury in Critically Ill COVID-19 Infection Patients

N/A

SUN

Opioid Use Disorder

N/A

Clinical Trials (1)

NCT06827288Adaptive Interventions for Emergency Department Patients With Opioid Use Disorder

N/A

Mindfulness

Depression, Unipolar

N/A

Clinical Trials (1)

NCT05400382Mindfulness to Reduce Post-cesarean Pain and Prevent Postpartum Depression

N/A

Packed Red Blood Cell Administration

Trauma Injury

N/A

Clinical Trials (1)

NCT06402669Extremity Trauma At a Level 1 Trauma Center

N/A

Orthopedic Surgery

Lactate Blood Increase

N/A

Clinical Trials (1)

NCT05611398Lactate Monitoring in Traumatic Long Bone Fractures Requiring Emergent Surgical Intervention

N/A

Vitamin C

Burns

N/A

Clinical Trials (1)

NCT05612867Low Dose Vitamin C in Burns >20% Compared to Previous Studies With High Dose Vitamin C

N/A

No Intervention

Rectal Foreign Body

N/A

Clinical Trials (1)

NCT05888363Management and Removal of Foreign Bodies in the Emergency Department

N/A

No Intervention

COVID-19

N/A

Clinical Trials (1)

NCT05897528Insulin Regulation and Severity of Severe Acute Respiratory Syndrome COVID-19 Infection

N/A

ARC-AAT Injection

Alpha-1 Antitrypsin Deficiency

Phase 1

Clinical Trials (1)

NCT02363946A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)

Phase 1

ARO-APOC3

Hypertriglyceridemia

Phase 1

Clinical Trials (1)

NCT03783377Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)

Phase 1

ARC-521

Hepatitis B

Phase 1

Clinical Trials (1)

NCT02797522A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)

Phase 1

ARO-HIF2

Clear Cell Renal Cell Carcinoma

Phase 1

Clinical Trials (1)

NCT04169711Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma

Phase 1

ARO-CFB

IgA Nephropathy

Phase 1

Clinical Trials (1)

NCT06209177Study of ARO-CFB in Adult Healthy Volunteers

Phase 1

VSA001 injection

Healthy Adult Volunteers

Phase 1

Clinical Trials (1)

NCT05757596Study of VSA001 Injection in Chinese Healthy Adult Volunteers

Phase 1

ARO-SOD1

Amyotrophic Lateral Sclerosis

Phase 1

Clinical Trials (1)

NCT05949294Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)

Phase 1

ARO-AAT Injection

Alpha 1-Antitrypsin Deficiency

Phase 1

Clinical Trials (1)

NCT03362242Study of ARO-AAT in Normal Adult Volunteers

Phase 1

Azithromycin Pill

Infections

Phase 1

Clinical Trials (1)

NCT06543290Azithromycin Before Induction

Phase 1

ARO-ATXN2

Spinocerebellar Ataxia Type 2

Phase 1

Clinical Trials (1)

NCT06672445Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2

Phase 1

ARO-MAPT

Alzheimer Disease

Phase 1/2

Clinical Trials (1)

NCT07221344Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease

Phase 1/2

ARO-MUC5AC

Chronic Obstructive Pulmonary Disease

Phase 1/2

Clinical Trials (1)

NCT05292950Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease

Phase 1/2

ARO-RAGE

Asthma

Phase 1/2

Clinical Trials (3)

NCT07241546Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma

Phase 2

NCT05276570Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease

Phase 1/2

ARO-ENaC

Cystic Fibrosis

Phase 1/2

Clinical Trials (1)

NCT04375514Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis

Phase 1/2

ARO-MMP7

Idiopathic Pulmonary Fibrosis

Phase 1/2

Clinical Trials (1)

NCT05537025Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis

Phase 1/2

ARO-INHBE

Obesity

Phase 1/2

Clinical Trials (1)

NCT06700538A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

Phase 1/2

ARO-HBV

Hepatitis B

Phase 1/2

Clinical Trials (1)

NCT03365947Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)

Phase 1/2

ARO-DIMERPA

Hyperlipidemia, Mixed

Phase 1/2

Clinical Trials (1)

NCT07223658Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia

Phase 1/2

ARO-ALK7

Obesity

Phase 1/2

Clinical Trials (1)

NCT06937203A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus

Phase 1/2

ARO-HSD

Non-alcoholic Steatohepatitis

Phase 1/2

Clinical Trials (1)

NCT04202354Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH

Phase 1/2

ARO-C3

C3 Glomerulopathy

Phase 1/2

Clinical Trials (1)

NCT05083364Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

Phase 1/2

ARO-DUX4

Facio-Scapulo-Humeral Dystrophy

Phase 1/2

Clinical Trials (1)

NCT06131983Study of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1

Phase 1/2

ARO-DM1

Myotonic Dystrophy 1

Phase 1/2

Clinical Trials (1)

NCT06138743Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy

Phase 1/2

ARO-APOC3

Dyslipidemias

Phase 2

Clinical Trials (1)

NCT05413135Study of ARO-APOC3 in Adults With Dyslipidemia

Phase 2

fazirsiran

Alpha 1-Antitrypsin Deficiency

Phase 2

Clinical Trials (2)

NCT03945292Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)

Phase 2

NCT03946449Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)

ARO-ANG3

Dyslipidemias

Phase 2

Clinical Trials (3)

NCT04832971Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

Phase 2

NCT05217667Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)

Phase 2

ARO-APOC3

Severe Hypertriglyceridemia

Phase 2

Clinical Trials (1)

NCT04720534Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

Phase 2

ARC-AAT Injection

Alpha-1 Antitrypsin Deficiency

Phase 2

Clinical Trials (1)

NCT02900183Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels

Phase 2

ARC-520

Hepatitis B

Phase 2

Clinical Trials (5)

NCT02065336A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection

Phase 2

NCT02349126Study of ARC-520 in Patient With Chronic Hepatitis B Virus

Calcium carbonate

Uterine Contraction

Phase 2/3

Clinical Trials (1)

NCT07056062Oral Calcium Supplementation in Labor

Phase 2/3

zodasiran

Homozygous Familial Hypercholesterolemia

Phase 3

Clinical Trials (2)

NCT07037771A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

Phase 3

NCT07473843Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

Tranexamic Acid

Hemorrhagic Shock

Phase 3

Clinical Trials (1)

NCT03469947California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA

Phase 3

plozasiran

Severe Hypertriglyceridemia

Phase 3

Clinical Trials (5)

NCT06347133Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Phase 3

NCT06347016Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Phase 3

Statins

Intracerebral Hemorrhage

Phase 3

Venofer 200 MG Per 10 ML Injection

Iron Deficiency Anemia of Pregnancy

Phase 3

Clinical Trials (1)

NCT06366698Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia

Phase 3

Bevacizumab

Pterygium

Phase 4

Clinical Trials (1)

NCT01736449Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management

Phase 4

Anti-hypertensive therapy

Hypertension

Phase 4

Arrowhead Pharmaceuticals(ARWR)

Should You Work at Arrowhead Pharmaceuticals?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (1)

Pipeline & Clinical Trials

Open Jobs (4)

Associate Director, Materials Compliance

Associate Director, Global Regulatory Operations (Regulatory Submissions and Publishing)

Associate Director, Drug Safety Operations

Associate Director/Director, Quality & Compliance (Drug Safety & Pharmacovigilance)

Financials (FY2025)

Visa Sponsorship